Efectividad predictiva de las escalas Framingham y PROCAM para el establecimiento de riesgo cardiovascular en pacientes con lupus eritematoso sistémico, en instituciones de tercer nivel de atención

Los pacientes con lupus eritematoso sistémico (LES) presentan factores de riesgos intrínsecos de la enfermedad, como la aterogénesis acelerada y el estado proinflamatorio crónico. En Colombia, las escalas Framingham y PROCAM se encuentran validadas para la prediccion de riesgo cardiovascular, no inc...

Full description

Autores:
Caballero Ríos, John Alexander
Cabrera Estrada, Erick Alexander
Tipo de recurso:
Trabajo de grado de pregrado
Fecha de publicación:
2024
Institución:
Universidad Libre
Repositorio:
RIU - Repositorio Institucional UniLibre
Idioma:
OAI Identifier:
oai:repository.unilibre.edu.co:10901/29412
Acceso en línea:
https://hdl.handle.net/10901/29412
Palabra clave:
Riesgo cardiovascular
Lupus eritematoso sistémico
PROCAM
Framingham
Cardiovascular risk
Systemic lupus erythematosus
PROCAM score
Framingham score
Lupus Eritematoso Sistémico
Enfermedades cardiovasculares
Estudios longitudinales
Framingham heart studies
Cardiovascular risk score
Rights
openAccess
License
http://creativecommons.org/licenses/by-nc-nd/2.5/co/
id RULIBRE2_4ff3a919f5cb84eaa7ec6a78464bc923
oai_identifier_str oai:repository.unilibre.edu.co:10901/29412
network_acronym_str RULIBRE2
network_name_str RIU - Repositorio Institucional UniLibre
repository_id_str
dc.title.spa.fl_str_mv Efectividad predictiva de las escalas Framingham y PROCAM para el establecimiento de riesgo cardiovascular en pacientes con lupus eritematoso sistémico, en instituciones de tercer nivel de atención
dc.title.alternative.spa.fl_str_mv Predictive effectiveness of the Framingham and PROCAM scales for establishing cardiovascular risk in patients with systemic lupus erythematosus, in third level care institutions
title Efectividad predictiva de las escalas Framingham y PROCAM para el establecimiento de riesgo cardiovascular en pacientes con lupus eritematoso sistémico, en instituciones de tercer nivel de atención
spellingShingle Efectividad predictiva de las escalas Framingham y PROCAM para el establecimiento de riesgo cardiovascular en pacientes con lupus eritematoso sistémico, en instituciones de tercer nivel de atención
Riesgo cardiovascular
Lupus eritematoso sistémico
PROCAM
Framingham
Cardiovascular risk
Systemic lupus erythematosus
PROCAM score
Framingham score
Lupus Eritematoso Sistémico
Enfermedades cardiovasculares
Estudios longitudinales
Framingham heart studies
Cardiovascular risk score
title_short Efectividad predictiva de las escalas Framingham y PROCAM para el establecimiento de riesgo cardiovascular en pacientes con lupus eritematoso sistémico, en instituciones de tercer nivel de atención
title_full Efectividad predictiva de las escalas Framingham y PROCAM para el establecimiento de riesgo cardiovascular en pacientes con lupus eritematoso sistémico, en instituciones de tercer nivel de atención
title_fullStr Efectividad predictiva de las escalas Framingham y PROCAM para el establecimiento de riesgo cardiovascular en pacientes con lupus eritematoso sistémico, en instituciones de tercer nivel de atención
title_full_unstemmed Efectividad predictiva de las escalas Framingham y PROCAM para el establecimiento de riesgo cardiovascular en pacientes con lupus eritematoso sistémico, en instituciones de tercer nivel de atención
title_sort Efectividad predictiva de las escalas Framingham y PROCAM para el establecimiento de riesgo cardiovascular en pacientes con lupus eritematoso sistémico, en instituciones de tercer nivel de atención
dc.creator.fl_str_mv Caballero Ríos, John Alexander
Cabrera Estrada, Erick Alexander
dc.contributor.advisor.none.fl_str_mv Ardila Pereira, Laura Cecilia
Salas Siado, José Ángel
Alcocer Olaciregui, Adalgisa Esther
dc.contributor.author.none.fl_str_mv Caballero Ríos, John Alexander
Cabrera Estrada, Erick Alexander
dc.subject.spa.fl_str_mv Riesgo cardiovascular
Lupus eritematoso sistémico
PROCAM
Framingham
topic Riesgo cardiovascular
Lupus eritematoso sistémico
PROCAM
Framingham
Cardiovascular risk
Systemic lupus erythematosus
PROCAM score
Framingham score
Lupus Eritematoso Sistémico
Enfermedades cardiovasculares
Estudios longitudinales
Framingham heart studies
Cardiovascular risk score
dc.subject.subjectenglish.spa.fl_str_mv Cardiovascular risk
Systemic lupus erythematosus
PROCAM score
Framingham score
dc.subject.lemb.spa.fl_str_mv Lupus Eritematoso Sistémico
Enfermedades cardiovasculares
Estudios longitudinales
Framingham heart studies
Cardiovascular risk score
description Los pacientes con lupus eritematoso sistémico (LES) presentan factores de riesgos intrínsecos de la enfermedad, como la aterogénesis acelerada y el estado proinflamatorio crónico. En Colombia, las escalas Framingham y PROCAM se encuentran validadas para la prediccion de riesgo cardiovascular, no incluyen variables del LES. Objetivo: establecer la efectividad predictiva de las escalas de Framingham y PROCAM para el establecimiento de riesgo cardiovascular en pacientes con LES. Metodologia: estudio de cohorte retrospectivo, multicéntrico, basado en registros disponibles entre 2010 y 2023, de pacientes s con LES atendidos en instituciones de tercer nivel de atención de la ciudad de Barranquilla. Se considero como cohorte expuesta, pacientes con puntaje riesgo cardiovascular mayor al 20% en la escalas Framingham y PROCAM. Resultados: . Durante los años de estudio registraron 42 casos de MACE, el hábito tabáquico, niveles elevados de colesterol (promedio LDL, 99,5 ± 40,9 mg/dL) y complemento disminuido tuvieron significancia estadística con su aparición. Los pacientes con MACE, fueron clasificados en su predominio como bajo riesgo (menor de 10%) según las escalas predictivas. La escala predictiva Framingham, mostro sensibilidad del 14%, especificidad del 87%, valor predictivo positivo (VPP) de 31%, valor predictivo negativo (VPN) del 71%, con AUC de 0.554. La escala predictiva PROCAM mostro una sensibilidad del 12%, especificidad del 90%, VPP 33%, VPN 71%, AUC de 0.593. Conclusión: se demostró una baja sensibilidad, valor predictivo positivo y AUC bajas, con modesto valor predictivo negativo y aceptable especificidad de las escalas predictivas Framingham y PROCAM en el cribaje de riesgo cardiovascular.
publishDate 2024
dc.date.accessioned.none.fl_str_mv 2024-07-11T18:57:53Z
dc.date.available.none.fl_str_mv 2024-07-11T18:57:53Z
dc.date.created.none.fl_str_mv 2024-07
dc.type.local.spa.fl_str_mv Tesis de Especialización
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_7a1f
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/bachelorThesis
format http://purl.org/coar/resource_type/c_7a1f
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/10901/29412
url https://hdl.handle.net/10901/29412
dc.relation.references.spa.fl_str_mv 1. Kiriakidou M, Ching CL. Systemic Lupus Erythematosus. Ann Intern Med. 2020 Jun 2;172(11):ITC81-ITC96.
2. Urowitz MB, Ibañez D, Su J, Gladman DD. Modified Framingham Risk Factor Score for Systemic Lupus Erythematosus. J Rheumatol. 2016 May;43(5):875-9.
3. Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum. 2013;43:77–95.
4. Koenig KF, Ribi C, Radosavac M, et al. Prevalence of vascular disease in systemic lupus erythematosus compared with type-1 diabetes mellitus: a cross-sectional study of two cohorts. Lupus. 2015;24:58–65.
5. Fernández D, Rincon D, Bernal S, et al. Prevalencia y características demográficas del Lupus Eritematoso Sistémico, Miopatía Inflamatoria, Osteoporosis, Polimialgia Reumática, Síndrome Sjögren y Vasculitis en Colombia, según información del Sistema Integral de Información de la Protección Social. 2017, (1);2-21.
6. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus [Internet]. 2006, (5):308–18.
7. Machengo K. Años ajustados por discapacidad en la población colombiana por lupus eritematoso sistémico en 2010-2020. Universidad del Bosque. 2021. Encontrado en: https://repositorio.unbosque.edu.co/bitstream/handle/20.500.12495/6763/ART%C3%8DCULO%20A%C3%91OS%20AJUSTADOS%20POR%20DISCAPACIDAD%20EN%20LA%20POBLACI%C3%93N%20COLOMBIANA%20POR%20LUPUS%20ERITEMATOSO%20SIST%C3%89MICO%20EN%202010.pdf?sequence=1&isAllowed=y
8. Fernández D, Rincon D, Bernal S, et al. Prevalencia y características demográficas del Lupus Eritematoso Sistémico, Miopatía Inflamatoria, Osteoporosis, Polimialgia Reumática, Síndrome Sjögren y Vasculitis en Colombia, según información del Sistema Integral de Información de la Protección Social. 2017, (1);2-21.
9. Caballero C, Torrenegra A, Meléndez M, Durante Y, Romero O, Barrera C, et al. Características clínico- epidemiológicas del lupus eritematoso sistémicos en los hospitales de tercer nivel de Barranquilla. Salud Uninorte. 1997; 12:9-12.
10. Ramírez C, Rojas J, Vanegas S, Cerquera Y, Puentes N, Alarcón C, et al. Caracterización clínica paraclínica y epidemiológica de los pacientes con Lupus Eritematoso Sistémico del Hospital Universitario Hernando Moncaleano Perdomo de Neiva. Revista médica. 2017; 23( 2 ): 23-28.
11. Sanchez-Arias A, Bobadilla-Serrano M, Dimas-Altamirano B, Gomez-Ortega M, Gonzalez-Gonzalez G. Enfermedad cardiovascular: primera causa de morbilidad en un hospital de tercer nivel. Rev Mex Cardiol 2016; 27 (s3): s98-s102.
12. Alegria-Ezquerra E, Alegria-Barrero A, Alegria-Barrero E. Estratificación del riesgo cardiovascular:importancia y aplicaciones.Rev Esp Cardiol Supl. 2012;12(C):8-11.
13. Auquilla K, Cabrera A, Sacoto M. Framingham versus PROCAM para establecer el riesgo cardiovascular. ¿Existe diferencia?. Revista de la Facultad de Ciencias Médicas de la Universidad de Cuenca. 2020 (38)2: 7-16.
14. Angulo E, Rivera N. Comorbilidad en lupus eritematoso sistémico, Reumatología Clínica. 2008; 4, 1: 17-21.
15. Alvarez-Ceballos J, Alvarez-Muñoz A, Carvajal-Gutierrez W, Gonzalez M, Duque J, Nieto-Cardenas O. Determinación del riesgo cardiovascular en una población.Rev Colomb Cardiol. 2017;24(4):334-341.
16. Alvarez-Cosmea A, Lopez-Fernandez V, Prieto-Diaz A, Diaz-Gonzalez L, Herrero-Puente P. PROCAM Y framingham por categorias:¿miden igualriesgo?. Medifam. 2002 abril;(2).
17. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation. 2002;105:310-5.
18. Berger JS, Jordan CO, Lloyd-Jones D, Blumenthal RS. Screening for cardiovascular risk in asymptomatic patients. J Am Coll Cardiol. 2010;55:1169-77.
19. McMahon M, Hahn BH, Skaggs BJ. Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention. Expert Rev Clin Immunol. 2011 Mar;7(2):227-41.
20. Aquino A, Acosta MI, Centurión OA, Avila G, Losantos J, Duarte M. Morbimortalidad cardiopulmonar en pacientes con lupus eritematoso sistémico. Mem. Inst. Investig. Cienc. Salud. 2015;13(2):127-38.
21. Batún J, Radillo H, Hernandez E. Riesgo cardiovascular en lupus eritematoso sistémico. Rev Colomb reumatol. 2016; 23(4):242-249.
22. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA, Jansen L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham study. Am J Epidemiol.1997;145:408–15.
23. Magro C, Salvatierra J, Rosales J, Raya E. Riesgo cardiovascular en el lupus eritematoso sistémico: factores implicados y métodos para su valoración. Semin Fund Esp Reumatol. 2012;13:95–102.
24. Roldan CA, Shively BK, Crawford MH. An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. N Engl J Med. 1996 Nov 7;335(19):1424–30
25. Urowitz MB, Gladman D, Ibañez D, Fortin P, SanchezGuerrero J, Bae S, et al. Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort. Lupus. 2007;16(9):731–5.
26. Patiño Giraldo Santiago, González Naranjo Luis Alonso, Vásquez Duque Gloria María, Restrepo Escobar Mauricio. Heart disease characteristics in patients with systemic lupus erythematosus. Iatreia. 2013; 26( 4 ): 447-456.
27. Ribeiro GG, Bonfá E, Sasdeli Neto R, Abe J, Caparbo VF, Borba EF, et al. Premature coronary artery calcification is associated with disease duration and bone mineral density in young female systemic lupus erythematosus patients. Lupus. 2010;19(1):27–33.
28. Ward MM. Outcomes of hospitalizations for myocardial infarctions and cerebrovascular accidents in patients with systemic lupus erythematosus. Arthritis Rheum. 2004 Oct;50(10):3170–6.
29. Law WG, Thong BY, Lian TY, Kong KO, Chng HH. Acute lupus myocarditis: clinical features and outcome of an oriental case series. Lupus. 2005;14(10):827–31.
30. Roldan CA, Shively BK, Crawford MH. An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. N Engl J Med. 1996 Nov 7;335(19):1424–30.
31. Szekanecz Z, Shoenfeld Y. Lupus and cardiovascular disease: the facts. Lupus. 2006;15(11 suppl):3-10.
32. Roberts WC, High ST. The heart in systemic lupus erythematosus. Curr Probl Cardiol. 1999 Jan;24(1):1–56.
33. Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus. 2000;9(3):170–5.
34. Calvo-Alén J, Toloza SMA, Fernández M, Bastian HM, Fessler BJ, Roseman JM, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients. Arthritis Rheum. 2005 Jul;52(7):2060-8. doi: 10.1002/art.21149.
35. Singh R, Yen E. SLE mortality remains disproportionately high, despite improvements over the last decade. Lupus. 2018;27(10):1577-1581
36. Moghaddam B, Marozoff S, Li L, Sayre EC, Zubieta JAA. All-cause and cause-specific mortality in systemic lupus erythematosus: a population-based study. Rheumatology (Oxford). 2021; 24, 61(1):367-376.
37. Bultink I, Vries F, Van Vollenhoven R, Lalmohamed A. Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls. Rheumatology. 2021; 60 (1): 207–216.
38. Monahan RC, Fronczek R, Eikenboom J, Middelkoop HAM, Beaart-van de Voorde LJJ, Terwindt GM, van der Wee NJA, Rosendaal FR, Huizinga TWJ, Kloppenburg M, Steup-Beekman GM. Mortality in patients with systemic lupus erythematosus and neuropsychiatric involvement: A retrospective analysis from a tertiary referral center in the Netherlands. Lupus. 2020 Dec;29(14):1892-1901.
39. Gómez-León Mandujano Amir, Amezcua-Guerra Luis Manuel. Manifestaciones cardiovasculares en el lupus eritematoso generalizado. Arch. Cardiol. Méx. [revista en la Internet]. 2008; 78( 4 ): 421-430.
40. Goldberg RJ, Urowitz MB, Ibañez D, et al. Risk factors for development of coronary artery disease in women with systemic lupus erythematosus. J Rheumatol 2009;11:2454–61.
41. Magder LS, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol 2012;176:708–19.
42. McMahon M, Seto R, Skaggs BJ. Cardiovascular disease in systemic lupus erythematosus. Rheumatol Immunol Res. 2021 Dec 15;2(3):157-172.
43. Álvarez J, Álvarez A., Carvajal W, González M, Duque J, Nieto O. Determinación del riesgo cardiovascular en una población. Rev. Colomb. Cardiol. 2017; 24( 4 ): 334-341.
44. Acosta MI, Pedretti GA, Aquino AM, Rojas E, Losanto J, Acosta ME et al. Eventos cardiovasculares en pacientes con lupus eritematoso sistémico y su asociación con factores de riesgo cardiovascular. Mem. Inst. Investig. Cienc. Salud. 2017; 15(1):80-87.
45. Ameer MA, Chaudhry H, Mushtaq J, Khan OS, Babar M, Hashim T, Zeb S, Tariq MA, Patlolla SR, Ali J, Hashim SN, Hashim S. An Overview of Systemic Lupus Erythematosus (SLE) Pathogenesis, Classification, and Management. Cureus. 2022 Oct 15;14(10):e30330.
46. Uggenti C, Lepelley A, Crow YJ. Self-Awareness: Nucleic Acid-Driven Inflammation and the Type I Interferonopathies. Annu Rev Immunol. 2019 Apr 26;37:247-267.
47. Gergianaki I, Bortoluzzi A, Bertsias G. Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2018 Apr;32(2):188-205.
48. Ungprasert P, Sagar V, Crowson CS, Amin S, Makol A, Ernste FC, Osborn TG, Moder KG, Niewold TB, Maradit-Kremers H, Ramsey-Goldman R, Chowdhary VR. Incidence of systemic lupus erythematosus in a population-based cohort using revised 1997 American College of Rheumatology and the 2012 Systemic Lupus International Collaborating Clinics classification criteria. Lupus. 2017 Mar;26(3):240-247
49. Kuo CF, Grainge MJ, Valdes AM, See LC, Luo SF, Yu KH, Zhang W, Doherty M. Familial Aggregation of Systemic Lupus Erythematosus and Coaggregation of Autoimmune Diseases in Affected Families. JAMA Intern Med. 2015 Sep;175(9):1518-26.
50. Ceccarelli F, Perricone C, Borgiani P, Ciccacci C, Rufini S, Cipriano E, Alessandri C, Spinelli FR, Sili Scavalli A, Novelli G, Valesini G, Conti F. Genetic Factors in Systemic Lupus Erythematosus: Contribution to Disease Phenotype. J Immunol Res. 2015;2015:745647.
51. Yaniv G, Twig G, Shor DB, Furer A, Sherer Y, Mozes O, Komisar O, Slonimsky E, Klang E, Lotan E, Welt M, Marai I, Shina A, Amital H, Shoenfeld Y. A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients. Autoimmun Rev. 2015 Jan;14(1):75-9.
52. Niu Z, Zhang P, Tong Y. Value of HLA-DR genotype in systemic lupus erythematosus and lupus nephritis: a meta-analysis. Int J Rheum Dis. 2015 Jan;18(1):17-28.
53. Bolin K, Sandling JK, Zickert A, Jönsen A, Sjöwall C, Svenungsson E, Bengtsson AA, Eloranta ML, Rönnblom L, Syvänen AC, Gunnarsson I, Nordmark G. Association of STAT4 polymorphism with severe renal insufficiency in lupus nephritis. PLoS One. 2013 Dec 27;8(12):e84450
54. Koga M, Kawasaki A, Ito I, Furuya T, Ohashi J, Kyogoku C, Ito S, Hayashi T, Matsumoto I, Kusaoi M, Takasaki Y, Hashimoto H, Sumida T, Tsuchiya N. Cumulative association of eight susceptibility genes with systemic lupus erythematosus in a Japanese female population. J Hum Genet. 2011 Jul;56(7):503-7.
55. Warchoł T, Lianeri M, Łącki JK, Olesińska M, Jagodziński PP. ITGAM Arg77His is associated with disease susceptibility, arthritis, and renal symptoms in systemic lupus erythematosus patients from a sample of the Polish population. DNA Cell Biol. 2011 Jan;30(1):33-8.
56. de Azevêdo Silva J, Monteiro Fernandes K, Trés Pancotto JA, Sotero Fragoso T, Donadi EA, Crovella S, Sandrin-Garcia P. Vitamin D receptor (VDR) gene polymorphisms and susceptibility to systemic lupus erythematosus clinical manifestations. Lupus. 2013 Oct;22(11):1110-7.
57. Singh A, Kamen DL. Potential benefits of vitamin D for patients with systemic lupus erythematosus. Dermatoendocrinol. 2012 Apr 1;4(2):146-51.
58. Kim-Howard X, Maiti AK, Anaya JM, Bruner GR, Brown E, Merrill JT, Edberg JC, Petri MA, Reveille JD, Ramsey-Goldman R, Alarcon GS, Vyse TJ, Gilkeson G, Kimberly RP, James JA, Guthridge JM, Harley JB, Nath SK. ITGAM coding variant (rs1143679) influences the risk of renal disease, discoid rash and immunological manifestations in patients with systemic lupus erythematosus with European ancestry. Ann Rheum Dis. 2010 Jul;69(7):1329-32.
59. da Silva Fonseca AM, de Azevedo Silva J, Pancotto JA, Donadi EA, Segat L, Crovella S, Sandrin-Garcia P. Polymorphisms in STK17A gene are associated with systemic lupus erythematosus and its clinical manifestations. Gene. 2013 Sep 25;527(2):435-9.
60. Perricone C, Agmon-Levin N, Ceccarelli F, Valesini G, Anaya JM, Shoenfeld Y. Genetics and autoantibodies. Immunol Res. 2013 Jul;56(2-3):206-19.
61. Podrebarac TA, Boisert DM, Goldstein R. Clinical correlates, serum autoantibodies and the role of the major histocompatibility complex in French Canadian and non-French Canadian Caucasians with SLE. Lupus. 1998;7(3):183-91.
62. Taylor KE, Chung SA, Graham RR, Ortmann WA, Lee AT, Langefeld CD, Jacob CO, Kamboh MI, Alarcón-Riquelme ME, Tsao BP, Moser KL, Gaffney PM, Harley JB, Petri M, Manzi S, Gregersen PK, Behrens TW, Criswell LA. Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes. PLoS Genet. 2011 Feb;7(2):e1001311.
63. Barbhaiya M, Costenbader KH. Environmental exposures and the development of systemic lupus erythematosus. Curr Opin Rheumatol. 2016 Sep;28(5):497-505.
64. Alarcón GS, Calvo-Alén J, McGwin G Jr, Uribe AG, Toloza SM, Roseman JM, Fernández M, Fessler BJ, Vilá LM, Ahn C, Tan FK, Reveille JD; LUMINA Study Group. Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time. Ann Rheum Dis. 2006 Sep;65(9):1168-74
65. Moon UY, Park SJ, Oh ST, Kim WU, Park SH, Lee SH, Cho CS, Kim HY, Lee WK, Lee SK. Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood. Arthritis Res Ther. 2004;6(4):R295-302.
66. Greiling TM, Dehner C, Chen X, Hughes K, Iñiguez AJ, Boccitto M, Ruiz DZ, Renfroe SC, Vieira SM, Ruff WE, Sim S, Kriegel C, Glanternik J, Chen X, Girardi M, Degnan P, Costenbader KH, Goodman AL, Wolin SL, Kriegel MA. Commensal orthologs of the human autoantigen Ro60 as triggers of autoimmunity in lupus. Sci Transl Med. 2018 Mar 28;10(434):eaan2306.
67. Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun. 2010 May;34(3):J258-65.
68. Freemer MM, King TE Jr, Criswell LA. Association of smoking with dsDNA autoantibody production in systemic lupus erythematosus. Ann Rheum Dis. 2006 May;65(5):581-4.
69. Gonzalez-Quintela A, Alende R, Gude F, Campos J, Rey J, Meijide LM, Fernandez-Merino C, Vidal C. Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities. Clin Exp Immunol. 2008 Jan;151(1):42-50.
70. Grimaldi-Bensouda L, Le Guern V, Kone-Paut I, Aubrun E, Fain O, Ruel M, Machet L, Viallard JF, Magy-Bertrand N, Daugas E, Rossignol M, Abenhaim L, Costedoat-Chalumeau N; PGRx Lupus Study Group. The risk of systemic lupus erythematosus associated with vaccines: an international case-control study. Arthritis Rheumatol. 2014 Jun;66(6):1559-67.
71. Brown JM, Pfau JC, Holian A. Immunoglobulin and lymphocyte responses following silica exposure in New Zealand mixed mice. Inhal Toxicol. 2004 Mar;16(3):133-9.
72. Bates MA, Brandenberger C, Langohr I, Kumagai K, Harkema JR, Holian A, Pestka JJ. Silica Triggers Inflammation and Ectopic Lymphoid Neogenesis in the Lungs in Parallel with Accelerated Onset of Systemic Autoimmunity and Glomerulonephritis in the Lupus-Prone NZBWF1 Mouse. PLoS One. 2015 May 15;10(5):e0125481
73. Kilburn KH, Warshaw RH. Prevalence of symptoms of systemic lupus erythematosus (SLE) and of fluorescent antinuclear antibodies associated with chronic exposure to trichloroethylene and other chemicals in well water. Environ Res. 1992 Feb;57(1):1-9.
74. Gilbert KM, Rowley B, Gomez-Acevedo H, Blossom SJ. Coexposure to mercury increases immunotoxicity of trichloroethylene. Toxicol Sci. 2011 Feb;119(2):281-92.
75. Cunningham M, Gilkeson G. Estrogen receptors in immunity and autoimmunity. Clin Rev Allergy Immunol. 2011 Feb;40(1):66-73.
76. Petri MA, Lahita RG, Van Vollenhoven RF, Merrill JT, Schiff M, Ginzler EM, Strand V, Kunz A, Gorelick KJ, Schwartz KE; GL601 Study Group. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2002 Jul;46(7):1820-9.
77. Costenbader KH, Feskanich D, Stampfer MJ, Karlson EW. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum. 2007 Apr;56(4):1251-62.
78. Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, Ruiz-Irastorza G, Hughes G. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016 Jun 16;2:16039.
79. Lövgren T, Eloranta ML, Båve U, Alm GV, Rönnblom L. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 2004 Jun;50(6):1861-72.
80. Ettinger R, Sims GP, Robbins R, Withers D, Fischer RT, Grammer AC, Kuchen S, Lipsky PE. IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells. J Immunol. 2007 Mar 1;178(5):2872-82.
81. Nambiar MP, Fisher CU, Warke VG, Krishnan S, Mitchell JP, Delaney N, Tsokos GC. Reconstitution of deficient T cell receptor zeta chain restores T cell signaling and augments T cell receptor/CD3-induced interleukin-2 production in patients with systemic lupus erythematosus. Arthritis Rheum. 2003 Jul;48(7):1948-55.
82. Javierre BM, Fernandez AF, Richter J, Al-Shahrour F, Martin-Subero JI, Rodriguez-Ubreva J, Berdasco M, Fraga MF, O'Hanlon TP, Rider LG, Jacinto FV, Lopez-Longo FJ, Dopazo J, Forn M, Peinado MA, Carreño L, Sawalha AH, Harley JB, Siebert R, Esteller M, Miller FW, Ballestar E. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res. 2010 Feb;20(2):170-9.
83. Song W, Craft J. T follicular helper cell heterogeneity: Time, space, and function. Immunol Rev. 2019 Mar;288(1):85-96.
84. Humrich JY, Riemekasten G. Low-dose interleukin-2 therapy for the treatment of systemic lupus erythematosus. Curr Opin Rheumatol. 2019 Mar;31(2):208-212.
85. Zhao Z, Ren J, Dai C, Kannapell CC, Wang H, Gaskin F, Fu SM. Nature of T cell epitopes in lupus antigens and HLA-DR determines autoantibody initiation and diversification. Ann Rheum Dis. 2019 Mar;78(3):380-390.
86. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003 Oct 16;349(16):1526-33.
87. Jiang C, Deshmukh US, Gaskin F, Bagavant H, Hanson J, David CS, Fu SM. Differential responses to Smith D autoantigen by mice with HLA-DR and HLA-DQ transgenes: dominant responses by HLA-DR3 transgenic mice with diversification of autoantibodies to small nuclear ribonucleoprotein, double-stranded DNA, and nuclear antigens. J Immunol. 2010 Jan 15;184(2):1085-91.
88. Bigler C, Schaller M, Perahud I, Osthoff M, Trendelenburg M. Autoantibodies against complement C1q specifically target C1q bound on early apoptotic cells. J Immunol. 2009 Sep 1;183(5):3512-21.
89. Maria NI, Davidson A. Renal Macrophages and Dendritic Cells in SLE Nephritis. Curr Rheumatol Rep. 2017 Nov 9;19(12):81.
90. Tydén H, Lood C, Gullstrand B, Nielsen CT, Heegaard NHH, Kahn R, Jönsen A, Bengtsson AA. Endothelial dysfunction is associated with activation of the type I interferon system and platelets in patients with systemic lupus erythematosus. RMD Open. 2017 Oct 25;3(2):e000508.
91. Liu Y, Kaplan MJ. Cardiovascular disease in systemic lupus erythematosus: an update. Curr Opin Rheumatol. 2018 Sep;30(5):441-448.
92. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271-7.
93. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012 Aug;64(8):2677-86
94. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019 Sep;78(9):1151-1159.
95. Kiriakidou M, Ching CL. Systemic Lupus Erythematosus. Ann Intern Med. 2020 Jun 2;172(11):ITC81-ITC96.
96. Filotico R, Mastrandrea V. Cutaneous lupus erythematosus: clinico-pathologic correlation. G Ital Dermatol Venereol. 2018 Apr;153(2):216-229.
97. Szczęch J, Samotij D, Werth VP, Reich A. Trigger factors of cutaneous lupus erythematosus: a review of current literature. Lupus. 2017 Jul;26(8):791-807.
98. Sanders CJ, Van Weelden H, Kazzaz GA, Sigurdsson V, Toonstra J, Bruijnzeel-Koomen CA. Photosensitivity in patients with lupus erythematosus: a clinical and photobiological study of 100 patients using a prolonged phototest protocol. Br J Dermatol. 2003 Jul;149(1):131-7.
99. Fabbri P, Amato L, Chiarini C, Moretti S, Massi D. Scarring alopecia in discoid lupus erythematosus: a clinical, histopathologic and immunopathologic study. Lupus. 2004;13(6):455-62.
100. Nico MM, Vilela MA, Rivitti EA, Lourenço SV. Oral lesions in lupus erythematosus: correlation with cutaneous lesions. Eur J Dermatol. 2008 Jul-Aug;18(4):376-81.
101. Zayat AS, Mahmoud K, Md Yusof MY, Mukherjee S, D'Agostino MA, Hensor EMA, Wakefield RJ, Conaghan PG, Edwards CJ, Emery P, Vital EM. Defining inflammatory musculoskeletal manifestations in systemic lupus erythematosus. Rheumatology (Oxford). 2019 Feb 1;58(2):304-312.
102. Mahmoud K, Zayat A, Vital EM. Musculoskeletal manifestations of systemic lupus erythmatosus. Curr Opin Rheumatol. 2017 Sep;29(5):486-492.
103. Zheng Y, Zheng Z, Zhang K, Zhu P. Osteonecrosis in systemic lupus erythematosus: Systematic insight from the epidemiology, pathogenesis, diagnosis and management. Autoimmun Rev. 2022 Feb;21(2):102992.
104. Cotton T, Niaki OZ, Zheng B, Pineau CA, Fritzler M, Vinet E, Clarke AE, Bernatsky S. Myositis in systemic lupus erythematosus. Lupus. 2021 Apr;30(4):615-619.
105. Yu C, Li P, Dang X, Zhang X, Mao Y, Chen X. Lupus nephritis: new progress in diagnosis and treatment. J Autoimmun. 2022 Oct;132:102871.
106. Almaani S, Meara A, Rovin BH. Update on Lupus Nephritis. Clin J Am Soc Nephrol. 2017 May 8;12(5):825-835.
107. Broder A, Mowrey WB, Khan HN, Jovanovic B, Londono-Jimenez A, Izmirly P, Putterman C. Tubulointerstitial damage predicts end stage renal disease in lupus nephritis with preserved to moderately impaired renal function: A retrospective cohort study. Semin Arthritis Rheum. 2018 Feb;47(4):545-551.
108. Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on Lupus Nephritis: Core Curriculum 2020. Am J Kidney Dis. 2020 Aug;76(2):265-281.
109. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004 Feb;15(2):241-50.
110. Ryu S, Fu W, Petri MA. Associates and predictors of pleurisy or pericarditis in SLE. Lupus Sci Med. 2017 Oct 23;4(1):e000221.
111. Aguilera-Pickens G, Abud-Mendoza C. Pulmonary manifestations in systemic lupus erythematosus: pleural involvement, acute pneumonitis, chronic interstitial lung disease and diffuse alveolar hemorrhage. Reumatol Clin (Engl Ed). 2018 Sep-Oct;14(5):294-300. English, Spanish.
112. Vonk MC, Vandecasteele E, van Dijk AP. Pulmonary hypertension in connective tissue diseases, new evidence and challenges. Eur J Clin Invest. 2021 Apr;51(4):e13453.
113. Deeb M, Tselios K, Gladman DD, Su J, Urowitz MB. Shrinking lung syndrome in systemic lupus erythematosus: a single-centre experience. Lupus. 2018 Mar;27(3):365-371.
114. Tselios K, Urowitz MB. Cardiovascular and Pulmonary Manifestations of Systemic Lupus Erythematosus. Curr Rheumatol Rev. 2017;13(3):206-218.
115. Weber BN, Stevens E, Barrett L, Bay C, Sinnette C, Brown JM, Divakaran S, Bibbo C, Hainer J, Dorbala S, Blankstein R, Liao K, Massarotti E, Costenbader K, Di Carli MF. Coronary Microvascular Dysfunction in Systemic Lupus Erythematosus. J Am Heart Assoc. 2021 Jul 6;10(13):e018555.
116. McMahon M, Skaggs BJ, Grossman JM, Sahakian L, Fitzgerald J, Wong WK, Lourenco EV, Ragavendra N, Charles-Schoeman C, Gorn A, Karpouzas GA, Taylor MB, Watson KE, Weisman MH, Wallace DJ, Hahn BH. A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheumatol. 2014 Jan;66(1):130-9.
117. Carrión-Barberà I, Salman-Monte TC, Vílchez-Oya F, Monfort J. Neuropsychiatric involvement in systemic lupus erythematosus: A review. Autoimmun Rev. 2021 Apr;20(4):102780.
118. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999 Apr;42(4):599-608.
119. Henegar CE, Eudy AM, Kharat V, Hill DD, Bennett D, Haight B. Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review. Lupus. 2016 May;25(6):617-26.
120. Sibbitt WL Jr, Brooks WM, Kornfeld M, Hart BL, Bankhurst AD, Roldan CA. Magnetic resonance imaging and brain histopathology in neuropsychiatric systemic lupus erythematosus. Semin Arthritis Rheum. 2010 Aug;40(1):32-52.
121. Brewer BN, Kamen DL. Gastrointestinal and Hepatic Disease in Systemic Lupus Erythematosus. Rheum Dis Clin North Am. 2018 Feb;44(1):165-175.
122. Dammacco R. Systemic lupus erythematosus and ocular involvement: an overview. Clin Exp Med. 2018 May;18(2):135-149.
123. Santacruz JC, Mantilla MJ, Rueda I, Pulido S, Rodriguez-Salas G, Londono J. A Practical Perspective of the Hematologic Manifestations of Systemic Lupus Erythematosus. Cureus. 2022 Mar 7;14(3):e22938.
124. Carli L, Tani C, Vagnani S, Signorini V, Mosca M. Leukopenia, lymphopenia, and neutropenia in systemic lupus erythematosus: Prevalence and clinical impact--A systematic literature review. Semin Arthritis Rheum. 2015 Oct;45(2):190-4.
125. Nashi RA, Shmerling RH. Antinuclear Antibody Testing for the Diagnosis of Systemic Lupus Erythematosus. Med Clin North Am. 2021 Mar;105(2):387-396.
126. Wang X, Xia Y. Anti-double Stranded DNA Antibodies: Origin, Pathogenicity, and Targeted Therapies. Front Immunol. 2019 Jul 17;10:1667.
127. Emad Y, Gheita T, Darweesh H, Klooster P, Gamal R, Fathi H, El-Shaarawy N, Gamil M, Hawass M, El-Refai RM, Al-Hanafi H, Abd-Ellatif S, Ismail A, Rasker J. Antibodies to extractable nuclear antigens (ENAS) in systemic lupus erythematosus patients: correlations with clinical manifestations and disease activity. Reumatismo. 2018 Jul 6;70(2):85-91.
128. Thanou A, Jupe E, Purushothaman M, Niewold TB, Munroe ME. Clinical disease activity and flare in SLE: Current concepts and novel biomarkers. J Autoimmun. 2021 May;119:102615.
129. Pego-Reigosa JM, Cobo-Ibáñez T, Calvo-Alén J, Loza-Santamaría E, Rahman A, Muñoz-Fernández S, Rúa-Figueroa Í. Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: a systematic review. Arthritis Care Res (Hoboken). 2013 Nov;65(11):1775-85.
130. Ruiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. Rheumatology (Oxford). 2020 Dec 5;59(Suppl5):v69-v81.
131. van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, Kleoudis CS, Zhong ZJ, Freimuth W. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012 Aug;71(8):1343-9.
132. Petri MA, Mease PJ, Merrill JT, Lahita RG, Iannini MJ, Yocum DE, Ginzler EM, Katz RS, Gluck OS, Genovese MC, Van Vollenhoven R, Kalunian KC, Manzi S, Greenwald MW, Buyon JP, Olsen NJ, Schiff MH, Kavanaugh AF, Caldwell JR, Ramsey-Goldman R, St Clair EW, Goldman AL, Egan RM, Polisson RP, Moder KG, Rothfield NF, Spencer RT, Hobbs K, Fessler BJ, Calabrese LH, Moreland LW, Cohen SB, Quarles BJ, Strand V, Gurwith M, Schwartz KE. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum. 2004 Sep;50(9):2858-68.
133. Zeher M, Doria A, Lan J, Aroca G, Jayne D, Boletis I, Hiepe F, Prestele H, Bernhardt P, Amoura Z. Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus. 2011 Dec;20(14):1484-93.
134. Lobos J, Brotons C. Factores de riesgo cardiovascular y atención primaria: evaluación e intervención. Aten Primaria. 2011; 43(12):668---677.
135. Galán AM. Valoración del riesgo cardiovascular: ¿qué tabla utilizar? Atención Primaria. 2003; 32(10).
136. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, et al. American Association of Clínical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23(s2):1-87.
137. Berger S, Jordan CO, Lloyd-Jones D, Blumenthal RS. Screening for Cardiovascular Risk in Asymptomatic Patients. J Am Coll Cardiol. March 23, 2010; 55(12):1169-77.
138. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clínical Practice Guidelines. Circulation. 2019;140(11):e563-e95.
139. Brotons C, Moral I, Soriano N, Cuixart L, Osorio D, Bottaro D, et al. Impacto de la utilización de las diferentes tablas SCORE en el cálculo del riesgo cardiovascular. Rev Esp Cardiol. 2014;67(2):94-100.
140. Doria A, Iaccarino L, Sarzi-Puttini P, Atzeni F, Turriel M, Petri M. Cardiac involvement in systemic lupus erythematosus. Lupus. 2005; 14:683-6.
141. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111-88.
142. Mejia S, Zuñiga C. Diabetes mellitus como factor de riesgo de demencia en la población adulta mayor mexicana. Neurol. 2011 Oct 1; 53(7): 397–405.
143. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007;30(3):753-9.
144. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957-67
145. Warburton DER, Bredin SSD. Health benefits of physical activity: a systematic review of current systematic reviews. Curr Opin Cardiol. 2017;32(5):541-56.
146. Mok CC, Poon WL, Lai JP, Wong CK, Chiu SM, Lun SW, et al. Metabolic syndrome, endothelial injury, and subclinical atherosclerosis in patients with systemic lupus erythematosus. Scand J Rheumatol. 2010;39:42–9.
147. Chung CP, Avalos I, Oeser A, Gebretsadik T, Shintani A, Raggi P, et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis. 2007;66:208–14.
148. Danesh J, Wheeler J, Hirschfield G, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2008; 350: 1387-97.
149. Manzur F, Alvear C, Alayón AN. Papel de la proteína C reactiva en las enfermedades cardiovasculares. Rev Colomb Cardiol. 2011;18:273–8.
150. Panoulas V, Douglas K, Stavropoulos-Kalinoglou A, Metsios G, Nightingale P, Kita M, et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology. 2008;47(1):72-5
151. Symmons D, Gabriel S. Epidemiology of CVD in rheumatic disease, whit a focus on RA and SLE. Nat Rev Rheumtol. 2011;7:399-408.
152. Bartoloni E, Shoenfeld Y, Gerli R. Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: two faces of the same coin. Arthritis Care Res. 2011;63:178-83.
153. Fasano S, Pierro L, Pantano I, et al. Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus. J Rheumatol 2017;44:1032–8.
154. Schanberg LE, Sandborg C, Barnhart HX, et al. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum 2012;64:285–96.
155. Álvarez Cosmea A., López Fernández V., Prieto Díaz M. A., Díaz González L., Herrero Puente P., Vázquez Álvarez J. et al . PROCAM y Framingham por categorías: ¿miden igual riesgo?. Medifam [Internet]. 2002 Abr [citado 2023 Jun 16] ; 12( 4 ): 40-49.
156. Sans S, Fitzgerald AP, Royo D, Conroy R, Graham I. Calibración de la tabla SCORE de riesgo cardiovascular para España. Rev Esp Cardiol. 2007;60(5):476-85
157. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37:2315–81.
158. Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. The Lancet. 2014 ;383(9921):999–1008. DOI: 10.1016/ S0140-6736(13)61752-3
159. Ruiz JS. Modelos europeos: PROCAM y SCORE. En: Control Global del Riesgo Cardiometabólico La disfunción endotelial como diana preferencial. Madrid: Díaz de Santos; 2012.
160. Nery MW, Martelli CMT, Aparecida Silveira E, Sousa CA de, Falco M de O, Castro A de CO de, et al. Cardiovascular risk assessment: A comparison of the Framingham, PROCAM, and DAD equations in HIV-infected persons. Sci World J. 2013;2013:1–9. DOI: 10.1155/2013/969281
161. Muñoz OM, Rodríguez NI, Ruiz Á, Rondón M. Validación de los modelos de predicción de Framingham y PROCAM como estimadores del riesgo cardiovascular en una población colombiana. Rev Colomb Cardiol. 2014;21(4):202–12. DOI: 10.1016/j. rccar.2014.02.001.
162. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;12;97(18):1837-47.
163. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation. 2002;105:310-5.
164. Thygesen K, Alpert J, ChaitmanB, White H, Jaffe A, Morrow D, et al. Consenso ESC 2018 sobre la cuarta definición universal del infarto de miocardio. Rev Esp Cardiol. 2019;72(1) :72.e1-e27.
165. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol (Hoboken NJ). 2019;71:1400---12.
166. Unger T, Borhgi C, Charchar F, Poulter N, Stegiou G, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020 Jun;75(6):1334-1357.
167. Cáliz R, Del Campo P, Galindo M, López F, Martínez M, Santamaría A, et al. Recomendaciones de la Sociedad Española de Reumatología sobre síndrome antifosfolípido primario. Parte I: Diagnóstico, evaluación y tratamiento. Reumatol Clin. 2020;16(2):71–86.
168. Merino J. Utilidad diagnóstica de la velocidad de sedimentación globular. Med Integral 2002;39(7):325-9.
169. Amezcua L, Springall R, Bojalil R. Proteína C reactiva: aspectos cardiovasculares de una proteína de fase aguda. Arch Cardiol Mex 2007; 77: 58-66.
170. Magro-Checa, C., Salvatierra, J., Rosales-Alexander, J. L., & Raya Álvarez, E. (2012). Riesgo cardiovascular en el lupus eritematoso sistémico: factores implicados y métodos para su valoración. Seminarios de La Fundación Española de Reumatología, 13(3), 95–102.
171. Tian J, Zhang D, Yao X, Huang Y, Lu Q. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis. 2023;82(3):351-356. doi:10.1136/ard-2022-223035
172. Reis-Neto ETD, Monticielo OA, Daher M, Lopes F, Angrimani D, Klumb EM. Life expectancy and death pattern associated with systemic lupus erythematosus diagnosis in Brazil between 2000 and 2019. Lupus. 2024;33(5):536-542. doi:10.1177/09612033241236383
173. Bartol-Puyal FA, Chacón González M, Arias-Peso B, et al. Vision-Related Quality of Life in Patients with Systemic Lupus Erythematosus. Healthcare (Basel). 2024;12(5):540.
174. Sun C, Qin W, Zhang YH, et al. Prevalence and risk of metabolic syndrome in patients with systemic lupus erythematosus: A meta-analysis. Int J Rheum Dis. 2017;20(8):917-928.
175. Nikolopoulos D, Fanouriakis A, Boumpas DT. Cerebrovascular Events in Systemic Lupus Erythematosus: Diagnosis and Management. Mediterr J Rheumatol. 2019 Mar 28;30(1):7-15.
176. Quintana, Rosana, Pons-Estel, Guillermo J., Serrano, Rosa, Pons-Estel, Bernardo A., & Bruce, Ian N.. (2021). Aterosclerosis acelerada y enfermedad cardiovascular en el lupus eritematoso sistémico. Revista Colombiana de Reumatología , 28 (Supl. 1), 21-30.
177. Riancho-Zarrabeitia L, Martínez-Taboada V, Rúa-Figueroa I, et al. Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality. Lupus. 2020;29(12):1556-1565.
178. Rachdi I, Daoud F, Zoubeidi H, et al. Arterial Hypertension in Systemic Lupus Erythematosus: About 40 Cases. Saudi J Kidney Dis Transpl. 2020;31(4):814-820.
179. Lin YJ, Chien CC, Ho CH, Chen HA, Chen CY. Increased risk of type 2 diabetes in patients with systemic lupus erythematosus: A nationwide cohort study in Taiwan. Medicine (Baltimore). 2022;101(51):e32520.
180. Vedder D, Nurmohamed MT. Verhoogd cardiovasculair risico door glucocorticoïden [Increased cardiovascular risk due to glucocorticoids: how strong is the evidence?]. Ned Tijdschr Geneeskd. 2021;165:D5841.
181. Chua MHY, Ng IAT, W L-Cheung M, Mak A. Association Between Cigarette Smoking and Systemic Lupus Erythematosus: An Updated Multivariate Bayesian Metaanalysis. J Rheumatol. 2020;47(10):1514-1521.
182. Siegel CH, Sammaritano LR. Systemic Lupus Erythematosus: A Review JAMA. 2024;331(17):1480-1491.
183. Barile-Fabris L, Hernández-Cabrera MF, Barragan-Garfias JA. Vasculitis in systemic lupus erythematosus. Curr Rheumatol Rep. 2014;16(9):440.
184. Ramos-Casals M, Nardi N, Lagrutta M, et al. Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. Medicine (Baltimore). 2006;85(2):95-104.
185. Szabó MZ, Szodoray P, Kiss E. Dyslipidemia in systemic lupus erythematosus. Immunol Res. 2017;65(2):543-550.
186. Bruce IN, Urowitz MB, Gladmann DD, Hallett DC. The natural history of hypercholesterinemia in SLE. J Rheumatol. 1999;26: 2137–43.
187. Carter AM. Complement activation: an emerging player in the pathogenesis of cardiovascular disease. Scientifica (Cairo). 2012;2012:402783.
188. Aviña-Zubieta JA, To F, Vostretsova K, De Vera M, Sayre EC, Esdaile JM. Risk of Myocardial Infarction and Stroke in Newly Diagnosed Systemic Lupus Erythematosus: A General Population-Based Study. Arthritis Care Res (Hoboken). 2017 Jun;69(6):849-856.
189. Lin CY, Shih CC, Yeh CC, Chou WH, Chen TL, Liao CC. Increased risk of acute myocardial infarction and mortality in patients with systemic lupus erythematosus: two nationwide retrospective cohort studies. Int J Cardiol 2014; 176: 847-51.
190. Batún-Garrido JAJ, García-Padrón OA, Hernández-Núñez E, Olán F, Salas-Magaña M. Síndrome metabólico y actividad de la enfermedad en pacientes con lupus eritematoso sistémico. Med. interna Méx. [revista en la Internet]. 2017 Ago [citado 2024 Jun 02] ; 33( 4 ): 443-451.
191. Navarro M, Ramírez V, Lizardo M, López M, et al. Lipoproteína de baja densidad pequeña y densa y riesgo cardiovascular en pacientes con lupus eritematoso sistémico. Comunidad y Salud . 2017; 15( 1 ): 53-62
192. Olbrich H, Kridin K, Zirpel H, Sadik C, Terheyden P, Thaci P, et al. Cutaneous lupus erythematosus is associated with an increased risk of cardiac and vascular diseases: a large-scale, propensity-matched global retrospective cohort study. eBioMedicine. 2023;93: 104639.
193. Liang MH, Mandl LA, Costenbader K, et al. Atherosclerotic Vascular Disease in Systemic Lupus Erythematosus. J Natl Med Assoc. 2002;94(9):813–819
194. Sivakumaran J, Harvey P, Omar A, Tayer-Shifman O, Urowitz MB, Gladman DD, Anderson N, Su J, Touma Z. Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus. Lupus Sci Med. 2021 May;8(1):e000448.
dc.rights.uri.spa.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.rights.license.spa.fl_str_mv Atribución-NoComercial-SinDerivadas 2.5 Colombia
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.coar.spa.fl_str_mv http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-nd/2.5/co/
Atribución-NoComercial-SinDerivadas 2.5 Colombia
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.spa.fl_str_mv PDF
dc.coverage.spatial.spa.fl_str_mv Barranquilla
institution Universidad Libre
bitstream.url.fl_str_mv http://repository.unilibre.edu.co/bitstream/10901/29412/4/CABALLERO.pdf.jpg
http://repository.unilibre.edu.co/bitstream/10901/29412/5/Autorizacion%20Caballero.pdf.jpg
http://repository.unilibre.edu.co/bitstream/10901/29412/3/license.txt
http://repository.unilibre.edu.co/bitstream/10901/29412/1/CABALLERO.pdf
http://repository.unilibre.edu.co/bitstream/10901/29412/2/Autorizacion%20Caballero.pdf
bitstream.checksum.fl_str_mv 4c62e0a4a49e5d70c378b2414796c9c4
8c3d0935573217876e3e8a32f6f3ff9b
8a4605be74aa9ea9d79846c1fba20a33
3f278eda40ed716e7d66bc8eeb485080
806b7430e791c562b0550ae3942bbad9
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional Unilibre
repository.mail.fl_str_mv repositorio@unilibrebog.edu.co
_version_ 1814090592165036032
spelling Ardila Pereira, Laura CeciliaSalas Siado, José ÁngelAlcocer Olaciregui, Adalgisa EstherCaballero Ríos, John AlexanderCabrera Estrada, Erick AlexanderBarranquilla2024-07-11T18:57:53Z2024-07-11T18:57:53Z2024-07https://hdl.handle.net/10901/29412Los pacientes con lupus eritematoso sistémico (LES) presentan factores de riesgos intrínsecos de la enfermedad, como la aterogénesis acelerada y el estado proinflamatorio crónico. En Colombia, las escalas Framingham y PROCAM se encuentran validadas para la prediccion de riesgo cardiovascular, no incluyen variables del LES. Objetivo: establecer la efectividad predictiva de las escalas de Framingham y PROCAM para el establecimiento de riesgo cardiovascular en pacientes con LES. Metodologia: estudio de cohorte retrospectivo, multicéntrico, basado en registros disponibles entre 2010 y 2023, de pacientes s con LES atendidos en instituciones de tercer nivel de atención de la ciudad de Barranquilla. Se considero como cohorte expuesta, pacientes con puntaje riesgo cardiovascular mayor al 20% en la escalas Framingham y PROCAM. Resultados: . Durante los años de estudio registraron 42 casos de MACE, el hábito tabáquico, niveles elevados de colesterol (promedio LDL, 99,5 ± 40,9 mg/dL) y complemento disminuido tuvieron significancia estadística con su aparición. Los pacientes con MACE, fueron clasificados en su predominio como bajo riesgo (menor de 10%) según las escalas predictivas. La escala predictiva Framingham, mostro sensibilidad del 14%, especificidad del 87%, valor predictivo positivo (VPP) de 31%, valor predictivo negativo (VPN) del 71%, con AUC de 0.554. La escala predictiva PROCAM mostro una sensibilidad del 12%, especificidad del 90%, VPP 33%, VPN 71%, AUC de 0.593. Conclusión: se demostró una baja sensibilidad, valor predictivo positivo y AUC bajas, con modesto valor predictivo negativo y aceptable especificidad de las escalas predictivas Framingham y PROCAM en el cribaje de riesgo cardiovascular.Universidad Libre Seccional Barranquilla -- Facultad de Ciencias de la Salud -- Especialización en Medicina InternaPatients with systemic lupus erythematosus (SLE) present intrinsic risk factors for the disease, such as accelerated atherogenesis and a chronic proinflammatory state. In Colombia, the Framingham and PROCAM scales are validated for the prediction of cardiovascular risk; they do not include SLE variables. Objective: to establish the predictive effectiveness of the Framingham and PROCAM scales for establishing cardiovascular risk in patients with SLE. Methodology: retrospective, multicenter cohort study, based on records available between 2010 and 2023, of patients with SLE treated in tertiary care institutions in the city of Barranquilla. The exposed cohort was considered to be patients with a cardiovascular risk score greater than 20% on the Framingham and PROCAM scales. Results: . During the study years, 42 cases of MACE were recorded; smoking, high cholesterol levels (average LDL, 99.5 ± 40.9 mg/dL) and decreased complement had statistical significance with its appearance. Patients with MACE were predominantly classified as low risk (less than 10%) according to predictive scales. The Framingham predictive scale showed sensitivity of 14%, specificity of 87%, positive predictive value (PPV) of 31%, negative predictive value (NPV) of 71%, with AUC of 0.554. The PROCAM predictive scale showed a sensitivity of 12%, specificity of 90%, PPV 33%, NPV 71%, AUC of 0.593. Conclusion: low sensitivity, positive predictive value and low AUC were demonstrated, with modest negative predictive value and acceptable specificity of the Framingham and PROCAM predictive scales in cardiovascular risk screening.PDFhttp://creativecommons.org/licenses/by-nc-nd/2.5/co/Atribución-NoComercial-SinDerivadas 2.5 Colombiainfo:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Riesgo cardiovascularLupus eritematoso sistémicoPROCAMFraminghamCardiovascular riskSystemic lupus erythematosusPROCAM scoreFramingham scoreLupus Eritematoso SistémicoEnfermedades cardiovascularesEstudios longitudinalesFramingham heart studiesCardiovascular risk scoreEfectividad predictiva de las escalas Framingham y PROCAM para el establecimiento de riesgo cardiovascular en pacientes con lupus eritematoso sistémico, en instituciones de tercer nivel de atenciónPredictive effectiveness of the Framingham and PROCAM scales for establishing cardiovascular risk in patients with systemic lupus erythematosus, in third level care institutionsTesis de Especializaciónhttp://purl.org/coar/resource_type/c_7a1finfo:eu-repo/semantics/bachelorThesis1. Kiriakidou M, Ching CL. Systemic Lupus Erythematosus. Ann Intern Med. 2020 Jun 2;172(11):ITC81-ITC96.2. Urowitz MB, Ibañez D, Su J, Gladman DD. Modified Framingham Risk Factor Score for Systemic Lupus Erythematosus. J Rheumatol. 2016 May;43(5):875-9.3. Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum. 2013;43:77–95.4. Koenig KF, Ribi C, Radosavac M, et al. Prevalence of vascular disease in systemic lupus erythematosus compared with type-1 diabetes mellitus: a cross-sectional study of two cohorts. Lupus. 2015;24:58–65.5. Fernández D, Rincon D, Bernal S, et al. Prevalencia y características demográficas del Lupus Eritematoso Sistémico, Miopatía Inflamatoria, Osteoporosis, Polimialgia Reumática, Síndrome Sjögren y Vasculitis en Colombia, según información del Sistema Integral de Información de la Protección Social. 2017, (1);2-21.6. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus [Internet]. 2006, (5):308–18.7. Machengo K. Años ajustados por discapacidad en la población colombiana por lupus eritematoso sistémico en 2010-2020. Universidad del Bosque. 2021. Encontrado en: https://repositorio.unbosque.edu.co/bitstream/handle/20.500.12495/6763/ART%C3%8DCULO%20A%C3%91OS%20AJUSTADOS%20POR%20DISCAPACIDAD%20EN%20LA%20POBLACI%C3%93N%20COLOMBIANA%20POR%20LUPUS%20ERITEMATOSO%20SIST%C3%89MICO%20EN%202010.pdf?sequence=1&isAllowed=y8. Fernández D, Rincon D, Bernal S, et al. Prevalencia y características demográficas del Lupus Eritematoso Sistémico, Miopatía Inflamatoria, Osteoporosis, Polimialgia Reumática, Síndrome Sjögren y Vasculitis en Colombia, según información del Sistema Integral de Información de la Protección Social. 2017, (1);2-21.9. Caballero C, Torrenegra A, Meléndez M, Durante Y, Romero O, Barrera C, et al. Características clínico- epidemiológicas del lupus eritematoso sistémicos en los hospitales de tercer nivel de Barranquilla. Salud Uninorte. 1997; 12:9-12.10. Ramírez C, Rojas J, Vanegas S, Cerquera Y, Puentes N, Alarcón C, et al. Caracterización clínica paraclínica y epidemiológica de los pacientes con Lupus Eritematoso Sistémico del Hospital Universitario Hernando Moncaleano Perdomo de Neiva. Revista médica. 2017; 23( 2 ): 23-28.11. Sanchez-Arias A, Bobadilla-Serrano M, Dimas-Altamirano B, Gomez-Ortega M, Gonzalez-Gonzalez G. Enfermedad cardiovascular: primera causa de morbilidad en un hospital de tercer nivel. Rev Mex Cardiol 2016; 27 (s3): s98-s102.12. Alegria-Ezquerra E, Alegria-Barrero A, Alegria-Barrero E. Estratificación del riesgo cardiovascular:importancia y aplicaciones.Rev Esp Cardiol Supl. 2012;12(C):8-11.13. Auquilla K, Cabrera A, Sacoto M. Framingham versus PROCAM para establecer el riesgo cardiovascular. ¿Existe diferencia?. Revista de la Facultad de Ciencias Médicas de la Universidad de Cuenca. 2020 (38)2: 7-16.14. Angulo E, Rivera N. Comorbilidad en lupus eritematoso sistémico, Reumatología Clínica. 2008; 4, 1: 17-21.15. Alvarez-Ceballos J, Alvarez-Muñoz A, Carvajal-Gutierrez W, Gonzalez M, Duque J, Nieto-Cardenas O. Determinación del riesgo cardiovascular en una población.Rev Colomb Cardiol. 2017;24(4):334-341.16. Alvarez-Cosmea A, Lopez-Fernandez V, Prieto-Diaz A, Diaz-Gonzalez L, Herrero-Puente P. PROCAM Y framingham por categorias:¿miden igualriesgo?. Medifam. 2002 abril;(2).17. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation. 2002;105:310-5.18. Berger JS, Jordan CO, Lloyd-Jones D, Blumenthal RS. Screening for cardiovascular risk in asymptomatic patients. J Am Coll Cardiol. 2010;55:1169-77.19. McMahon M, Hahn BH, Skaggs BJ. Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention. Expert Rev Clin Immunol. 2011 Mar;7(2):227-41.20. Aquino A, Acosta MI, Centurión OA, Avila G, Losantos J, Duarte M. Morbimortalidad cardiopulmonar en pacientes con lupus eritematoso sistémico. Mem. Inst. Investig. Cienc. Salud. 2015;13(2):127-38.21. Batún J, Radillo H, Hernandez E. Riesgo cardiovascular en lupus eritematoso sistémico. Rev Colomb reumatol. 2016; 23(4):242-249.22. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA, Jansen L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham study. Am J Epidemiol.1997;145:408–15.23. Magro C, Salvatierra J, Rosales J, Raya E. Riesgo cardiovascular en el lupus eritematoso sistémico: factores implicados y métodos para su valoración. Semin Fund Esp Reumatol. 2012;13:95–102.24. Roldan CA, Shively BK, Crawford MH. An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. N Engl J Med. 1996 Nov 7;335(19):1424–3025. Urowitz MB, Gladman D, Ibañez D, Fortin P, SanchezGuerrero J, Bae S, et al. Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort. Lupus. 2007;16(9):731–5.26. Patiño Giraldo Santiago, González Naranjo Luis Alonso, Vásquez Duque Gloria María, Restrepo Escobar Mauricio. Heart disease characteristics in patients with systemic lupus erythematosus. Iatreia. 2013; 26( 4 ): 447-456.27. Ribeiro GG, Bonfá E, Sasdeli Neto R, Abe J, Caparbo VF, Borba EF, et al. Premature coronary artery calcification is associated with disease duration and bone mineral density in young female systemic lupus erythematosus patients. Lupus. 2010;19(1):27–33.28. Ward MM. Outcomes of hospitalizations for myocardial infarctions and cerebrovascular accidents in patients with systemic lupus erythematosus. Arthritis Rheum. 2004 Oct;50(10):3170–6.29. Law WG, Thong BY, Lian TY, Kong KO, Chng HH. Acute lupus myocarditis: clinical features and outcome of an oriental case series. Lupus. 2005;14(10):827–31.30. Roldan CA, Shively BK, Crawford MH. An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. N Engl J Med. 1996 Nov 7;335(19):1424–30.31. Szekanecz Z, Shoenfeld Y. Lupus and cardiovascular disease: the facts. Lupus. 2006;15(11 suppl):3-10.32. Roberts WC, High ST. The heart in systemic lupus erythematosus. Curr Probl Cardiol. 1999 Jan;24(1):1–56.33. Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus. 2000;9(3):170–5.34. Calvo-Alén J, Toloza SMA, Fernández M, Bastian HM, Fessler BJ, Roseman JM, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients. Arthritis Rheum. 2005 Jul;52(7):2060-8. doi: 10.1002/art.21149.35. Singh R, Yen E. SLE mortality remains disproportionately high, despite improvements over the last decade. Lupus. 2018;27(10):1577-158136. Moghaddam B, Marozoff S, Li L, Sayre EC, Zubieta JAA. All-cause and cause-specific mortality in systemic lupus erythematosus: a population-based study. Rheumatology (Oxford). 2021; 24, 61(1):367-376.37. Bultink I, Vries F, Van Vollenhoven R, Lalmohamed A. Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls. Rheumatology. 2021; 60 (1): 207–216.38. Monahan RC, Fronczek R, Eikenboom J, Middelkoop HAM, Beaart-van de Voorde LJJ, Terwindt GM, van der Wee NJA, Rosendaal FR, Huizinga TWJ, Kloppenburg M, Steup-Beekman GM. Mortality in patients with systemic lupus erythematosus and neuropsychiatric involvement: A retrospective analysis from a tertiary referral center in the Netherlands. Lupus. 2020 Dec;29(14):1892-1901.39. Gómez-León Mandujano Amir, Amezcua-Guerra Luis Manuel. Manifestaciones cardiovasculares en el lupus eritematoso generalizado. Arch. Cardiol. Méx. [revista en la Internet]. 2008; 78( 4 ): 421-430.40. Goldberg RJ, Urowitz MB, Ibañez D, et al. Risk factors for development of coronary artery disease in women with systemic lupus erythematosus. J Rheumatol 2009;11:2454–61.41. Magder LS, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol 2012;176:708–19.42. McMahon M, Seto R, Skaggs BJ. Cardiovascular disease in systemic lupus erythematosus. Rheumatol Immunol Res. 2021 Dec 15;2(3):157-172.43. Álvarez J, Álvarez A., Carvajal W, González M, Duque J, Nieto O. Determinación del riesgo cardiovascular en una población. Rev. Colomb. Cardiol. 2017; 24( 4 ): 334-341.44. Acosta MI, Pedretti GA, Aquino AM, Rojas E, Losanto J, Acosta ME et al. Eventos cardiovasculares en pacientes con lupus eritematoso sistémico y su asociación con factores de riesgo cardiovascular. Mem. Inst. Investig. Cienc. Salud. 2017; 15(1):80-87.45. Ameer MA, Chaudhry H, Mushtaq J, Khan OS, Babar M, Hashim T, Zeb S, Tariq MA, Patlolla SR, Ali J, Hashim SN, Hashim S. An Overview of Systemic Lupus Erythematosus (SLE) Pathogenesis, Classification, and Management. Cureus. 2022 Oct 15;14(10):e30330.46. Uggenti C, Lepelley A, Crow YJ. Self-Awareness: Nucleic Acid-Driven Inflammation and the Type I Interferonopathies. Annu Rev Immunol. 2019 Apr 26;37:247-267.47. Gergianaki I, Bortoluzzi A, Bertsias G. Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2018 Apr;32(2):188-205.48. Ungprasert P, Sagar V, Crowson CS, Amin S, Makol A, Ernste FC, Osborn TG, Moder KG, Niewold TB, Maradit-Kremers H, Ramsey-Goldman R, Chowdhary VR. Incidence of systemic lupus erythematosus in a population-based cohort using revised 1997 American College of Rheumatology and the 2012 Systemic Lupus International Collaborating Clinics classification criteria. Lupus. 2017 Mar;26(3):240-24749. Kuo CF, Grainge MJ, Valdes AM, See LC, Luo SF, Yu KH, Zhang W, Doherty M. Familial Aggregation of Systemic Lupus Erythematosus and Coaggregation of Autoimmune Diseases in Affected Families. JAMA Intern Med. 2015 Sep;175(9):1518-26.50. Ceccarelli F, Perricone C, Borgiani P, Ciccacci C, Rufini S, Cipriano E, Alessandri C, Spinelli FR, Sili Scavalli A, Novelli G, Valesini G, Conti F. Genetic Factors in Systemic Lupus Erythematosus: Contribution to Disease Phenotype. J Immunol Res. 2015;2015:745647.51. Yaniv G, Twig G, Shor DB, Furer A, Sherer Y, Mozes O, Komisar O, Slonimsky E, Klang E, Lotan E, Welt M, Marai I, Shina A, Amital H, Shoenfeld Y. A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients. Autoimmun Rev. 2015 Jan;14(1):75-9.52. Niu Z, Zhang P, Tong Y. Value of HLA-DR genotype in systemic lupus erythematosus and lupus nephritis: a meta-analysis. Int J Rheum Dis. 2015 Jan;18(1):17-28.53. Bolin K, Sandling JK, Zickert A, Jönsen A, Sjöwall C, Svenungsson E, Bengtsson AA, Eloranta ML, Rönnblom L, Syvänen AC, Gunnarsson I, Nordmark G. Association of STAT4 polymorphism with severe renal insufficiency in lupus nephritis. PLoS One. 2013 Dec 27;8(12):e8445054. Koga M, Kawasaki A, Ito I, Furuya T, Ohashi J, Kyogoku C, Ito S, Hayashi T, Matsumoto I, Kusaoi M, Takasaki Y, Hashimoto H, Sumida T, Tsuchiya N. Cumulative association of eight susceptibility genes with systemic lupus erythematosus in a Japanese female population. J Hum Genet. 2011 Jul;56(7):503-7.55. Warchoł T, Lianeri M, Łącki JK, Olesińska M, Jagodziński PP. ITGAM Arg77His is associated with disease susceptibility, arthritis, and renal symptoms in systemic lupus erythematosus patients from a sample of the Polish population. DNA Cell Biol. 2011 Jan;30(1):33-8.56. de Azevêdo Silva J, Monteiro Fernandes K, Trés Pancotto JA, Sotero Fragoso T, Donadi EA, Crovella S, Sandrin-Garcia P. Vitamin D receptor (VDR) gene polymorphisms and susceptibility to systemic lupus erythematosus clinical manifestations. Lupus. 2013 Oct;22(11):1110-7.57. Singh A, Kamen DL. Potential benefits of vitamin D for patients with systemic lupus erythematosus. Dermatoendocrinol. 2012 Apr 1;4(2):146-51.58. Kim-Howard X, Maiti AK, Anaya JM, Bruner GR, Brown E, Merrill JT, Edberg JC, Petri MA, Reveille JD, Ramsey-Goldman R, Alarcon GS, Vyse TJ, Gilkeson G, Kimberly RP, James JA, Guthridge JM, Harley JB, Nath SK. ITGAM coding variant (rs1143679) influences the risk of renal disease, discoid rash and immunological manifestations in patients with systemic lupus erythematosus with European ancestry. Ann Rheum Dis. 2010 Jul;69(7):1329-32.59. da Silva Fonseca AM, de Azevedo Silva J, Pancotto JA, Donadi EA, Segat L, Crovella S, Sandrin-Garcia P. Polymorphisms in STK17A gene are associated with systemic lupus erythematosus and its clinical manifestations. Gene. 2013 Sep 25;527(2):435-9.60. Perricone C, Agmon-Levin N, Ceccarelli F, Valesini G, Anaya JM, Shoenfeld Y. Genetics and autoantibodies. Immunol Res. 2013 Jul;56(2-3):206-19.61. Podrebarac TA, Boisert DM, Goldstein R. Clinical correlates, serum autoantibodies and the role of the major histocompatibility complex in French Canadian and non-French Canadian Caucasians with SLE. Lupus. 1998;7(3):183-91.62. Taylor KE, Chung SA, Graham RR, Ortmann WA, Lee AT, Langefeld CD, Jacob CO, Kamboh MI, Alarcón-Riquelme ME, Tsao BP, Moser KL, Gaffney PM, Harley JB, Petri M, Manzi S, Gregersen PK, Behrens TW, Criswell LA. Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes. PLoS Genet. 2011 Feb;7(2):e1001311.63. Barbhaiya M, Costenbader KH. Environmental exposures and the development of systemic lupus erythematosus. Curr Opin Rheumatol. 2016 Sep;28(5):497-505.64. Alarcón GS, Calvo-Alén J, McGwin G Jr, Uribe AG, Toloza SM, Roseman JM, Fernández M, Fessler BJ, Vilá LM, Ahn C, Tan FK, Reveille JD; LUMINA Study Group. Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time. Ann Rheum Dis. 2006 Sep;65(9):1168-7465. Moon UY, Park SJ, Oh ST, Kim WU, Park SH, Lee SH, Cho CS, Kim HY, Lee WK, Lee SK. Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood. Arthritis Res Ther. 2004;6(4):R295-302.66. Greiling TM, Dehner C, Chen X, Hughes K, Iñiguez AJ, Boccitto M, Ruiz DZ, Renfroe SC, Vieira SM, Ruff WE, Sim S, Kriegel C, Glanternik J, Chen X, Girardi M, Degnan P, Costenbader KH, Goodman AL, Wolin SL, Kriegel MA. Commensal orthologs of the human autoantigen Ro60 as triggers of autoimmunity in lupus. Sci Transl Med. 2018 Mar 28;10(434):eaan2306.67. Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun. 2010 May;34(3):J258-65.68. Freemer MM, King TE Jr, Criswell LA. Association of smoking with dsDNA autoantibody production in systemic lupus erythematosus. Ann Rheum Dis. 2006 May;65(5):581-4.69. Gonzalez-Quintela A, Alende R, Gude F, Campos J, Rey J, Meijide LM, Fernandez-Merino C, Vidal C. Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities. Clin Exp Immunol. 2008 Jan;151(1):42-50.70. Grimaldi-Bensouda L, Le Guern V, Kone-Paut I, Aubrun E, Fain O, Ruel M, Machet L, Viallard JF, Magy-Bertrand N, Daugas E, Rossignol M, Abenhaim L, Costedoat-Chalumeau N; PGRx Lupus Study Group. The risk of systemic lupus erythematosus associated with vaccines: an international case-control study. Arthritis Rheumatol. 2014 Jun;66(6):1559-67.71. Brown JM, Pfau JC, Holian A. Immunoglobulin and lymphocyte responses following silica exposure in New Zealand mixed mice. Inhal Toxicol. 2004 Mar;16(3):133-9.72. Bates MA, Brandenberger C, Langohr I, Kumagai K, Harkema JR, Holian A, Pestka JJ. Silica Triggers Inflammation and Ectopic Lymphoid Neogenesis in the Lungs in Parallel with Accelerated Onset of Systemic Autoimmunity and Glomerulonephritis in the Lupus-Prone NZBWF1 Mouse. PLoS One. 2015 May 15;10(5):e012548173. Kilburn KH, Warshaw RH. Prevalence of symptoms of systemic lupus erythematosus (SLE) and of fluorescent antinuclear antibodies associated with chronic exposure to trichloroethylene and other chemicals in well water. Environ Res. 1992 Feb;57(1):1-9.74. Gilbert KM, Rowley B, Gomez-Acevedo H, Blossom SJ. Coexposure to mercury increases immunotoxicity of trichloroethylene. Toxicol Sci. 2011 Feb;119(2):281-92.75. Cunningham M, Gilkeson G. Estrogen receptors in immunity and autoimmunity. Clin Rev Allergy Immunol. 2011 Feb;40(1):66-73.76. Petri MA, Lahita RG, Van Vollenhoven RF, Merrill JT, Schiff M, Ginzler EM, Strand V, Kunz A, Gorelick KJ, Schwartz KE; GL601 Study Group. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2002 Jul;46(7):1820-9.77. Costenbader KH, Feskanich D, Stampfer MJ, Karlson EW. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum. 2007 Apr;56(4):1251-62.78. Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, Ruiz-Irastorza G, Hughes G. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016 Jun 16;2:16039.79. Lövgren T, Eloranta ML, Båve U, Alm GV, Rönnblom L. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 2004 Jun;50(6):1861-72.80. Ettinger R, Sims GP, Robbins R, Withers D, Fischer RT, Grammer AC, Kuchen S, Lipsky PE. IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells. J Immunol. 2007 Mar 1;178(5):2872-82.81. Nambiar MP, Fisher CU, Warke VG, Krishnan S, Mitchell JP, Delaney N, Tsokos GC. Reconstitution of deficient T cell receptor zeta chain restores T cell signaling and augments T cell receptor/CD3-induced interleukin-2 production in patients with systemic lupus erythematosus. Arthritis Rheum. 2003 Jul;48(7):1948-55.82. Javierre BM, Fernandez AF, Richter J, Al-Shahrour F, Martin-Subero JI, Rodriguez-Ubreva J, Berdasco M, Fraga MF, O'Hanlon TP, Rider LG, Jacinto FV, Lopez-Longo FJ, Dopazo J, Forn M, Peinado MA, Carreño L, Sawalha AH, Harley JB, Siebert R, Esteller M, Miller FW, Ballestar E. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res. 2010 Feb;20(2):170-9.83. Song W, Craft J. T follicular helper cell heterogeneity: Time, space, and function. Immunol Rev. 2019 Mar;288(1):85-96.84. Humrich JY, Riemekasten G. Low-dose interleukin-2 therapy for the treatment of systemic lupus erythematosus. Curr Opin Rheumatol. 2019 Mar;31(2):208-212.85. Zhao Z, Ren J, Dai C, Kannapell CC, Wang H, Gaskin F, Fu SM. Nature of T cell epitopes in lupus antigens and HLA-DR determines autoantibody initiation and diversification. Ann Rheum Dis. 2019 Mar;78(3):380-390.86. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003 Oct 16;349(16):1526-33.87. Jiang C, Deshmukh US, Gaskin F, Bagavant H, Hanson J, David CS, Fu SM. Differential responses to Smith D autoantigen by mice with HLA-DR and HLA-DQ transgenes: dominant responses by HLA-DR3 transgenic mice with diversification of autoantibodies to small nuclear ribonucleoprotein, double-stranded DNA, and nuclear antigens. J Immunol. 2010 Jan 15;184(2):1085-91.88. Bigler C, Schaller M, Perahud I, Osthoff M, Trendelenburg M. Autoantibodies against complement C1q specifically target C1q bound on early apoptotic cells. J Immunol. 2009 Sep 1;183(5):3512-21.89. Maria NI, Davidson A. Renal Macrophages and Dendritic Cells in SLE Nephritis. Curr Rheumatol Rep. 2017 Nov 9;19(12):81.90. Tydén H, Lood C, Gullstrand B, Nielsen CT, Heegaard NHH, Kahn R, Jönsen A, Bengtsson AA. Endothelial dysfunction is associated with activation of the type I interferon system and platelets in patients with systemic lupus erythematosus. RMD Open. 2017 Oct 25;3(2):e000508.91. Liu Y, Kaplan MJ. Cardiovascular disease in systemic lupus erythematosus: an update. Curr Opin Rheumatol. 2018 Sep;30(5):441-448.92. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271-7.93. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012 Aug;64(8):2677-8694. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019 Sep;78(9):1151-1159.95. Kiriakidou M, Ching CL. Systemic Lupus Erythematosus. Ann Intern Med. 2020 Jun 2;172(11):ITC81-ITC96.96. Filotico R, Mastrandrea V. Cutaneous lupus erythematosus: clinico-pathologic correlation. G Ital Dermatol Venereol. 2018 Apr;153(2):216-229.97. Szczęch J, Samotij D, Werth VP, Reich A. Trigger factors of cutaneous lupus erythematosus: a review of current literature. Lupus. 2017 Jul;26(8):791-807.98. Sanders CJ, Van Weelden H, Kazzaz GA, Sigurdsson V, Toonstra J, Bruijnzeel-Koomen CA. Photosensitivity in patients with lupus erythematosus: a clinical and photobiological study of 100 patients using a prolonged phototest protocol. Br J Dermatol. 2003 Jul;149(1):131-7.99. Fabbri P, Amato L, Chiarini C, Moretti S, Massi D. Scarring alopecia in discoid lupus erythematosus: a clinical, histopathologic and immunopathologic study. Lupus. 2004;13(6):455-62.100. Nico MM, Vilela MA, Rivitti EA, Lourenço SV. Oral lesions in lupus erythematosus: correlation with cutaneous lesions. Eur J Dermatol. 2008 Jul-Aug;18(4):376-81.101. Zayat AS, Mahmoud K, Md Yusof MY, Mukherjee S, D'Agostino MA, Hensor EMA, Wakefield RJ, Conaghan PG, Edwards CJ, Emery P, Vital EM. Defining inflammatory musculoskeletal manifestations in systemic lupus erythematosus. Rheumatology (Oxford). 2019 Feb 1;58(2):304-312.102. Mahmoud K, Zayat A, Vital EM. Musculoskeletal manifestations of systemic lupus erythmatosus. Curr Opin Rheumatol. 2017 Sep;29(5):486-492.103. Zheng Y, Zheng Z, Zhang K, Zhu P. Osteonecrosis in systemic lupus erythematosus: Systematic insight from the epidemiology, pathogenesis, diagnosis and management. Autoimmun Rev. 2022 Feb;21(2):102992.104. Cotton T, Niaki OZ, Zheng B, Pineau CA, Fritzler M, Vinet E, Clarke AE, Bernatsky S. Myositis in systemic lupus erythematosus. Lupus. 2021 Apr;30(4):615-619.105. Yu C, Li P, Dang X, Zhang X, Mao Y, Chen X. Lupus nephritis: new progress in diagnosis and treatment. J Autoimmun. 2022 Oct;132:102871.106. Almaani S, Meara A, Rovin BH. Update on Lupus Nephritis. Clin J Am Soc Nephrol. 2017 May 8;12(5):825-835.107. Broder A, Mowrey WB, Khan HN, Jovanovic B, Londono-Jimenez A, Izmirly P, Putterman C. Tubulointerstitial damage predicts end stage renal disease in lupus nephritis with preserved to moderately impaired renal function: A retrospective cohort study. Semin Arthritis Rheum. 2018 Feb;47(4):545-551.108. Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on Lupus Nephritis: Core Curriculum 2020. Am J Kidney Dis. 2020 Aug;76(2):265-281.109. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004 Feb;15(2):241-50.110. Ryu S, Fu W, Petri MA. Associates and predictors of pleurisy or pericarditis in SLE. Lupus Sci Med. 2017 Oct 23;4(1):e000221.111. Aguilera-Pickens G, Abud-Mendoza C. Pulmonary manifestations in systemic lupus erythematosus: pleural involvement, acute pneumonitis, chronic interstitial lung disease and diffuse alveolar hemorrhage. Reumatol Clin (Engl Ed). 2018 Sep-Oct;14(5):294-300. English, Spanish.112. Vonk MC, Vandecasteele E, van Dijk AP. Pulmonary hypertension in connective tissue diseases, new evidence and challenges. Eur J Clin Invest. 2021 Apr;51(4):e13453.113. Deeb M, Tselios K, Gladman DD, Su J, Urowitz MB. Shrinking lung syndrome in systemic lupus erythematosus: a single-centre experience. Lupus. 2018 Mar;27(3):365-371.114. Tselios K, Urowitz MB. Cardiovascular and Pulmonary Manifestations of Systemic Lupus Erythematosus. Curr Rheumatol Rev. 2017;13(3):206-218.115. Weber BN, Stevens E, Barrett L, Bay C, Sinnette C, Brown JM, Divakaran S, Bibbo C, Hainer J, Dorbala S, Blankstein R, Liao K, Massarotti E, Costenbader K, Di Carli MF. Coronary Microvascular Dysfunction in Systemic Lupus Erythematosus. J Am Heart Assoc. 2021 Jul 6;10(13):e018555.116. McMahon M, Skaggs BJ, Grossman JM, Sahakian L, Fitzgerald J, Wong WK, Lourenco EV, Ragavendra N, Charles-Schoeman C, Gorn A, Karpouzas GA, Taylor MB, Watson KE, Weisman MH, Wallace DJ, Hahn BH. A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheumatol. 2014 Jan;66(1):130-9.117. Carrión-Barberà I, Salman-Monte TC, Vílchez-Oya F, Monfort J. Neuropsychiatric involvement in systemic lupus erythematosus: A review. Autoimmun Rev. 2021 Apr;20(4):102780.118. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999 Apr;42(4):599-608.119. Henegar CE, Eudy AM, Kharat V, Hill DD, Bennett D, Haight B. Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review. Lupus. 2016 May;25(6):617-26.120. Sibbitt WL Jr, Brooks WM, Kornfeld M, Hart BL, Bankhurst AD, Roldan CA. Magnetic resonance imaging and brain histopathology in neuropsychiatric systemic lupus erythematosus. Semin Arthritis Rheum. 2010 Aug;40(1):32-52.121. Brewer BN, Kamen DL. Gastrointestinal and Hepatic Disease in Systemic Lupus Erythematosus. Rheum Dis Clin North Am. 2018 Feb;44(1):165-175.122. Dammacco R. Systemic lupus erythematosus and ocular involvement: an overview. Clin Exp Med. 2018 May;18(2):135-149.123. Santacruz JC, Mantilla MJ, Rueda I, Pulido S, Rodriguez-Salas G, Londono J. A Practical Perspective of the Hematologic Manifestations of Systemic Lupus Erythematosus. Cureus. 2022 Mar 7;14(3):e22938.124. Carli L, Tani C, Vagnani S, Signorini V, Mosca M. Leukopenia, lymphopenia, and neutropenia in systemic lupus erythematosus: Prevalence and clinical impact--A systematic literature review. Semin Arthritis Rheum. 2015 Oct;45(2):190-4.125. Nashi RA, Shmerling RH. Antinuclear Antibody Testing for the Diagnosis of Systemic Lupus Erythematosus. Med Clin North Am. 2021 Mar;105(2):387-396.126. Wang X, Xia Y. Anti-double Stranded DNA Antibodies: Origin, Pathogenicity, and Targeted Therapies. Front Immunol. 2019 Jul 17;10:1667.127. Emad Y, Gheita T, Darweesh H, Klooster P, Gamal R, Fathi H, El-Shaarawy N, Gamil M, Hawass M, El-Refai RM, Al-Hanafi H, Abd-Ellatif S, Ismail A, Rasker J. Antibodies to extractable nuclear antigens (ENAS) in systemic lupus erythematosus patients: correlations with clinical manifestations and disease activity. Reumatismo. 2018 Jul 6;70(2):85-91.128. Thanou A, Jupe E, Purushothaman M, Niewold TB, Munroe ME. Clinical disease activity and flare in SLE: Current concepts and novel biomarkers. J Autoimmun. 2021 May;119:102615.129. Pego-Reigosa JM, Cobo-Ibáñez T, Calvo-Alén J, Loza-Santamaría E, Rahman A, Muñoz-Fernández S, Rúa-Figueroa Í. Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: a systematic review. Arthritis Care Res (Hoboken). 2013 Nov;65(11):1775-85.130. Ruiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. Rheumatology (Oxford). 2020 Dec 5;59(Suppl5):v69-v81.131. van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, Kleoudis CS, Zhong ZJ, Freimuth W. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012 Aug;71(8):1343-9.132. Petri MA, Mease PJ, Merrill JT, Lahita RG, Iannini MJ, Yocum DE, Ginzler EM, Katz RS, Gluck OS, Genovese MC, Van Vollenhoven R, Kalunian KC, Manzi S, Greenwald MW, Buyon JP, Olsen NJ, Schiff MH, Kavanaugh AF, Caldwell JR, Ramsey-Goldman R, St Clair EW, Goldman AL, Egan RM, Polisson RP, Moder KG, Rothfield NF, Spencer RT, Hobbs K, Fessler BJ, Calabrese LH, Moreland LW, Cohen SB, Quarles BJ, Strand V, Gurwith M, Schwartz KE. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum. 2004 Sep;50(9):2858-68.133. Zeher M, Doria A, Lan J, Aroca G, Jayne D, Boletis I, Hiepe F, Prestele H, Bernhardt P, Amoura Z. Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus. 2011 Dec;20(14):1484-93.134. Lobos J, Brotons C. Factores de riesgo cardiovascular y atención primaria: evaluación e intervención. Aten Primaria. 2011; 43(12):668---677.135. Galán AM. Valoración del riesgo cardiovascular: ¿qué tabla utilizar? Atención Primaria. 2003; 32(10).136. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, et al. American Association of Clínical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23(s2):1-87.137. Berger S, Jordan CO, Lloyd-Jones D, Blumenthal RS. Screening for Cardiovascular Risk in Asymptomatic Patients. J Am Coll Cardiol. March 23, 2010; 55(12):1169-77.138. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clínical Practice Guidelines. Circulation. 2019;140(11):e563-e95.139. Brotons C, Moral I, Soriano N, Cuixart L, Osorio D, Bottaro D, et al. Impacto de la utilización de las diferentes tablas SCORE en el cálculo del riesgo cardiovascular. Rev Esp Cardiol. 2014;67(2):94-100.140. Doria A, Iaccarino L, Sarzi-Puttini P, Atzeni F, Turriel M, Petri M. Cardiac involvement in systemic lupus erythematosus. Lupus. 2005; 14:683-6.141. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111-88.142. Mejia S, Zuñiga C. Diabetes mellitus como factor de riesgo de demencia en la población adulta mayor mexicana. Neurol. 2011 Oct 1; 53(7): 397–405.143. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007;30(3):753-9.144. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957-67145. Warburton DER, Bredin SSD. Health benefits of physical activity: a systematic review of current systematic reviews. Curr Opin Cardiol. 2017;32(5):541-56.146. Mok CC, Poon WL, Lai JP, Wong CK, Chiu SM, Lun SW, et al. Metabolic syndrome, endothelial injury, and subclinical atherosclerosis in patients with systemic lupus erythematosus. Scand J Rheumatol. 2010;39:42–9.147. Chung CP, Avalos I, Oeser A, Gebretsadik T, Shintani A, Raggi P, et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis. 2007;66:208–14.148. Danesh J, Wheeler J, Hirschfield G, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2008; 350: 1387-97.149. Manzur F, Alvear C, Alayón AN. Papel de la proteína C reactiva en las enfermedades cardiovasculares. Rev Colomb Cardiol. 2011;18:273–8.150. Panoulas V, Douglas K, Stavropoulos-Kalinoglou A, Metsios G, Nightingale P, Kita M, et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology. 2008;47(1):72-5151. Symmons D, Gabriel S. Epidemiology of CVD in rheumatic disease, whit a focus on RA and SLE. Nat Rev Rheumtol. 2011;7:399-408.152. Bartoloni E, Shoenfeld Y, Gerli R. Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: two faces of the same coin. Arthritis Care Res. 2011;63:178-83.153. Fasano S, Pierro L, Pantano I, et al. Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus. J Rheumatol 2017;44:1032–8.154. Schanberg LE, Sandborg C, Barnhart HX, et al. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum 2012;64:285–96.155. Álvarez Cosmea A., López Fernández V., Prieto Díaz M. A., Díaz González L., Herrero Puente P., Vázquez Álvarez J. et al . PROCAM y Framingham por categorías: ¿miden igual riesgo?. Medifam [Internet]. 2002 Abr [citado 2023 Jun 16] ; 12( 4 ): 40-49.156. Sans S, Fitzgerald AP, Royo D, Conroy R, Graham I. Calibración de la tabla SCORE de riesgo cardiovascular para España. Rev Esp Cardiol. 2007;60(5):476-85157. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37:2315–81.158. Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. The Lancet. 2014 ;383(9921):999–1008. DOI: 10.1016/ S0140-6736(13)61752-3159. Ruiz JS. Modelos europeos: PROCAM y SCORE. En: Control Global del Riesgo Cardiometabólico La disfunción endotelial como diana preferencial. Madrid: Díaz de Santos; 2012.160. Nery MW, Martelli CMT, Aparecida Silveira E, Sousa CA de, Falco M de O, Castro A de CO de, et al. Cardiovascular risk assessment: A comparison of the Framingham, PROCAM, and DAD equations in HIV-infected persons. Sci World J. 2013;2013:1–9. DOI: 10.1155/2013/969281161. Muñoz OM, Rodríguez NI, Ruiz Á, Rondón M. Validación de los modelos de predicción de Framingham y PROCAM como estimadores del riesgo cardiovascular en una población colombiana. Rev Colomb Cardiol. 2014;21(4):202–12. DOI: 10.1016/j. rccar.2014.02.001.162. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;12;97(18):1837-47.163. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation. 2002;105:310-5.164. Thygesen K, Alpert J, ChaitmanB, White H, Jaffe A, Morrow D, et al. Consenso ESC 2018 sobre la cuarta definición universal del infarto de miocardio. Rev Esp Cardiol. 2019;72(1) :72.e1-e27.165. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol (Hoboken NJ). 2019;71:1400---12.166. Unger T, Borhgi C, Charchar F, Poulter N, Stegiou G, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020 Jun;75(6):1334-1357.167. Cáliz R, Del Campo P, Galindo M, López F, Martínez M, Santamaría A, et al. Recomendaciones de la Sociedad Española de Reumatología sobre síndrome antifosfolípido primario. Parte I: Diagnóstico, evaluación y tratamiento. Reumatol Clin. 2020;16(2):71–86.168. Merino J. Utilidad diagnóstica de la velocidad de sedimentación globular. Med Integral 2002;39(7):325-9.169. Amezcua L, Springall R, Bojalil R. Proteína C reactiva: aspectos cardiovasculares de una proteína de fase aguda. Arch Cardiol Mex 2007; 77: 58-66.170. Magro-Checa, C., Salvatierra, J., Rosales-Alexander, J. L., & Raya Álvarez, E. (2012). Riesgo cardiovascular en el lupus eritematoso sistémico: factores implicados y métodos para su valoración. Seminarios de La Fundación Española de Reumatología, 13(3), 95–102.171. Tian J, Zhang D, Yao X, Huang Y, Lu Q. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis. 2023;82(3):351-356. doi:10.1136/ard-2022-223035172. Reis-Neto ETD, Monticielo OA, Daher M, Lopes F, Angrimani D, Klumb EM. Life expectancy and death pattern associated with systemic lupus erythematosus diagnosis in Brazil between 2000 and 2019. Lupus. 2024;33(5):536-542. doi:10.1177/09612033241236383173. Bartol-Puyal FA, Chacón González M, Arias-Peso B, et al. Vision-Related Quality of Life in Patients with Systemic Lupus Erythematosus. Healthcare (Basel). 2024;12(5):540.174. Sun C, Qin W, Zhang YH, et al. Prevalence and risk of metabolic syndrome in patients with systemic lupus erythematosus: A meta-analysis. Int J Rheum Dis. 2017;20(8):917-928.175. Nikolopoulos D, Fanouriakis A, Boumpas DT. Cerebrovascular Events in Systemic Lupus Erythematosus: Diagnosis and Management. Mediterr J Rheumatol. 2019 Mar 28;30(1):7-15.176. Quintana, Rosana, Pons-Estel, Guillermo J., Serrano, Rosa, Pons-Estel, Bernardo A., & Bruce, Ian N.. (2021). Aterosclerosis acelerada y enfermedad cardiovascular en el lupus eritematoso sistémico. Revista Colombiana de Reumatología , 28 (Supl. 1), 21-30.177. Riancho-Zarrabeitia L, Martínez-Taboada V, Rúa-Figueroa I, et al. Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality. Lupus. 2020;29(12):1556-1565.178. Rachdi I, Daoud F, Zoubeidi H, et al. Arterial Hypertension in Systemic Lupus Erythematosus: About 40 Cases. Saudi J Kidney Dis Transpl. 2020;31(4):814-820.179. Lin YJ, Chien CC, Ho CH, Chen HA, Chen CY. Increased risk of type 2 diabetes in patients with systemic lupus erythematosus: A nationwide cohort study in Taiwan. Medicine (Baltimore). 2022;101(51):e32520.180. Vedder D, Nurmohamed MT. Verhoogd cardiovasculair risico door glucocorticoïden [Increased cardiovascular risk due to glucocorticoids: how strong is the evidence?]. Ned Tijdschr Geneeskd. 2021;165:D5841.181. Chua MHY, Ng IAT, W L-Cheung M, Mak A. Association Between Cigarette Smoking and Systemic Lupus Erythematosus: An Updated Multivariate Bayesian Metaanalysis. J Rheumatol. 2020;47(10):1514-1521.182. Siegel CH, Sammaritano LR. Systemic Lupus Erythematosus: A Review JAMA. 2024;331(17):1480-1491.183. Barile-Fabris L, Hernández-Cabrera MF, Barragan-Garfias JA. Vasculitis in systemic lupus erythematosus. Curr Rheumatol Rep. 2014;16(9):440.184. Ramos-Casals M, Nardi N, Lagrutta M, et al. Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. Medicine (Baltimore). 2006;85(2):95-104.185. Szabó MZ, Szodoray P, Kiss E. Dyslipidemia in systemic lupus erythematosus. Immunol Res. 2017;65(2):543-550.186. Bruce IN, Urowitz MB, Gladmann DD, Hallett DC. The natural history of hypercholesterinemia in SLE. J Rheumatol. 1999;26: 2137–43.187. Carter AM. Complement activation: an emerging player in the pathogenesis of cardiovascular disease. Scientifica (Cairo). 2012;2012:402783.188. Aviña-Zubieta JA, To F, Vostretsova K, De Vera M, Sayre EC, Esdaile JM. Risk of Myocardial Infarction and Stroke in Newly Diagnosed Systemic Lupus Erythematosus: A General Population-Based Study. Arthritis Care Res (Hoboken). 2017 Jun;69(6):849-856.189. Lin CY, Shih CC, Yeh CC, Chou WH, Chen TL, Liao CC. Increased risk of acute myocardial infarction and mortality in patients with systemic lupus erythematosus: two nationwide retrospective cohort studies. Int J Cardiol 2014; 176: 847-51.190. Batún-Garrido JAJ, García-Padrón OA, Hernández-Núñez E, Olán F, Salas-Magaña M. Síndrome metabólico y actividad de la enfermedad en pacientes con lupus eritematoso sistémico. Med. interna Méx. [revista en la Internet]. 2017 Ago [citado 2024 Jun 02] ; 33( 4 ): 443-451.191. Navarro M, Ramírez V, Lizardo M, López M, et al. Lipoproteína de baja densidad pequeña y densa y riesgo cardiovascular en pacientes con lupus eritematoso sistémico. Comunidad y Salud . 2017; 15( 1 ): 53-62192. Olbrich H, Kridin K, Zirpel H, Sadik C, Terheyden P, Thaci P, et al. Cutaneous lupus erythematosus is associated with an increased risk of cardiac and vascular diseases: a large-scale, propensity-matched global retrospective cohort study. eBioMedicine. 2023;93: 104639.193. Liang MH, Mandl LA, Costenbader K, et al. Atherosclerotic Vascular Disease in Systemic Lupus Erythematosus. J Natl Med Assoc. 2002;94(9):813–819194. Sivakumaran J, Harvey P, Omar A, Tayer-Shifman O, Urowitz MB, Gladman DD, Anderson N, Su J, Touma Z. Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus. Lupus Sci Med. 2021 May;8(1):e000448.THUMBNAILCABALLERO.pdf.jpgCABALLERO.pdf.jpgPortadaimage/jpeg70234http://repository.unilibre.edu.co/bitstream/10901/29412/4/CABALLERO.pdf.jpg4c62e0a4a49e5d70c378b2414796c9c4MD54Autorizacion Caballero.pdf.jpgAutorizacion Caballero.pdf.jpgIM Thumbnailimage/jpeg27742http://repository.unilibre.edu.co/bitstream/10901/29412/5/Autorizacion%20Caballero.pdf.jpg8c3d0935573217876e3e8a32f6f3ff9bMD55LICENSElicense.txtlicense.txttext/plain; charset=utf-81748http://repository.unilibre.edu.co/bitstream/10901/29412/3/license.txt8a4605be74aa9ea9d79846c1fba20a33MD53ORIGINALCABALLERO.pdfCABALLERO.pdfArchivo del trabajo de gradoapplication/pdf1801367http://repository.unilibre.edu.co/bitstream/10901/29412/1/CABALLERO.pdf3f278eda40ed716e7d66bc8eeb485080MD51Autorizacion Caballero.pdfAutorizacion Caballero.pdfFormulario autorizacionapplication/pdf11644523http://repository.unilibre.edu.co/bitstream/10901/29412/2/Autorizacion%20Caballero.pdf806b7430e791c562b0550ae3942bbad9MD5210901/29412oai:repository.unilibre.edu.co:10901/294122024-08-28 06:01:24.952Repositorio Institucional Unilibrerepositorio@unilibrebog.edu.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

Publicaciones similares